Production (Stage)
Adaptimmune Therapeutics plc
ADAP
$0.2801
$0.00572.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.30% | 1,294.81% | 458.83% | 2,399.63% | -88.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.30% | 1,294.81% | 458.83% | 2,399.63% | -88.07% |
| Cost of Revenue | -15.54% | 17.96% | -9.22% | 34.98% | 37.81% |
| Gross Profit | 23.97% | -9.01% | 121.65% | 453.46% | -233.90% |
| SG&A Expenses | 9.57% | 199.64% | 31.63% | -4.93% | 34.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.52% | 58.48% | 3.02% | 18.97% | 36.77% |
| Operating Income | 10.54% | -51.76% | 68.52% | 252.98% | -762.82% |
| Income Before Tax | 2.02% | -49.31% | 62.63% | 438.24% | -2,988.44% |
| Income Tax Expenses | 9.32% | 358.08% | 20.96% | -22.65% | -15.84% |
| Earnings from Continuing Operations | 1.89% | -54.88% | 61.37% | 425.03% | -4,781.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.89% | -54.88% | 61.37% | 425.03% | -4,781.76% |
| EBIT | 10.54% | -51.76% | 68.52% | 252.98% | -762.82% |
| EBITDA | 10.39% | -55.60% | 72.88% | 267.41% | -600.50% |
| EPS Basic | 7.68% | -37.44% | 65.81% | 334.89% | -3,282.54% |
| Normalized Basic EPS | 11.05% | -36.65% | 66.86% | 218.06% | -541.28% |
| EPS Diluted | 7.68% | -46.45% | 65.81% | 300.00% | -3,333.87% |
| Normalized Diluted EPS | 11.05% | -36.65% | 66.86% | 216.13% | -544.44% |
| Average Basic Shares Outstanding | 6.26% | 12.69% | 13.02% | 38.38% | 46.39% |
| Average Diluted Shares Outstanding | 6.26% | 12.69% | 13.02% | 40.70% | 45.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |